1. Home
  2. NAVI vs AUPH Comparison

NAVI vs AUPH Comparison

Compare NAVI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navient Corporation

NAVI

Navient Corporation

HOLD

Current Price

$13.00

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.94

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAVI
AUPH
Founded
1973
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.6B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
NAVI
AUPH
Price
$13.00
$15.94
Analyst Decision
Hold
Buy
Analyst Count
6
4
Target Price
$13.83
$17.25
AVG Volume (30 Days)
942.3K
1.1M
Earning Date
01-28-2026
11-04-2025
Dividend Yield
4.92%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.55
Revenue
$443,000,000.00
$265,808,000.00
Revenue This Year
N/A
$21.76
Revenue Next Year
N/A
$16.45
P/E Ratio
N/A
$28.99
Revenue Growth
N/A
20.62
52 Week Low
$10.53
$6.55
52 Week High
$16.07
$16.54

Technical Indicators

Market Signals
Indicator
NAVI
AUPH
Relative Strength Index (RSI) 57.36 55.71
Support Level $12.77 $15.64
Resistance Level $13.21 $16.54
Average True Range (ATR) 0.26 0.38
MACD -0.02 -0.08
Stochastic Oscillator 40.12 57.55

Price Performance

Historical Comparison
NAVI
AUPH

About NAVI Navient Corporation

Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in three segments: Federal Education Loans, Consumer Lending, and Business Processing. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: